A randomized trial of tenecteplase versus alteplase for acute ischemic stroke. N Engl J Med. 181. Haley EC Jr, Thompson JL, Grotta JC, Lyden PD, Hemmen TG, Brown DL, Fanale C, Libman R, Kwiatkowski TG, Llinas RH, et al; for the Tenecteplase in Stroke Investigators. Phase IIB/III trial of tenecteplase in acute ischemic stroke: results of a prematurely termi- nated randomized clinical trial. Stroke. 2010;41:707 711. doi: 182. Logallo N, Novotny V, Assmus J, Kvistad CE, Alteheld L, R nning OM, Thommessen B, Amthor KF, Ihle-Hansen H, Kurz M, et al. Tenecteplase versus alteplase for management of acute ischaemic stroke (NOR- TEST): a phase 3, randomised, open-label, blinded endpoint trial. Lancet 183. Hacke W, Furlan AJ, Al-Rawi Y, Davalos A, Fiebach JB, Gruber F, KasteM,LipkaLJ,PedrazaS,RinglebPA,etal.Intravenousdesmoteplase in patients with acute ischaemic stroke selected by MRI perfusion- diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study. Lancet Neurol. 184. Hacke W,Albers G,Al-RawiY, Bogousslavsky J, DavalosA, Eliasziw M, Fischer M, Furlan A, Kaste M, Lees KR, et al; for the DIAS Study Group. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke. 2005;36:66 73. doi: 185. von Kummer R, Mori E, Truelsen T, Jensen JS, Gr nning BA, Fiebach JB, Lovblad KO, Pedraza S, Romero JM, Chabriat H, et al; for the DIAS-4 Investigators. Desmoteplase 3 to 9 hours after major artery occlusion stroke: the DIAS-4 Trial (Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke). Stroke. 2016;47:2880 2887. doi: 186. Albers GW, von Kummer R, Truelsen T, Jensen JK, Ravn GM, Gr nning BA, Chabriat H, Chang KC, Davalos AE, Ford GA, et al; DIAS-3 Investigators. 